How Will The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Expand At A CAGR Of 9.9% Through 2029?
Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
How Is The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Expected To Grow In Terms Of Size?
The market size for inhibitors of the calcitonin gene-related peptide (CGRP) has seen robust growth in the past few years. Projected growth is from $2.87 billion in 2024 to $3.14 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 9.6%. The expansion during the historic period is due to factors such as greater investments in research and development, approval of more new drugs, a rise in demand for non-opioid analgesics, and an increased emphasis on personalized medicine.
Over the coming years, the market size for inhibitors of the calcitonin gene-related peptide (cgrp) is predicted to experience robust expansion, reaching a value of “$4.58 billion in 2029” with a compound annual growth rate (CAGR) of 9.9%. This anticipated growth for the forecasted period is ascribable to several factors such as the increasing incidence of migraines, expanded use of preventative migraine treatments, improved patient knowledge, and heightened healthcare spending. Key future trends include improvements in drug formulation technology, the incorporation of digital health resources, advancements in precision medicine, and tech upgrades in biosimilars.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24182&type=smp
Which Factors Are Steering Growth In The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
The growth of the calcitonin gene-related peptide (CGRP) inhibitors market is anticipated to be driven by the rising incidence of migraines. Migraines, which are severe headaches often causing pulsating pain on one side of the head, come with symptoms like nausea, vomiting, and pronounced sensitivity to light and sound. The rising occurrence of these headaches can be attributed to increasing stress levels, which trigger neural pathways. CGRP inhibitors play a crucial role in managing migraines by providing a focused preventative approach and compatibility with both immediate and long-term treatment plans. They lessen the frequency and intensity of these headaches by successfully blocking CGRP receptors, which in turn enhances patient comfort and everyday functionality. For example, a report by the National Library of Medicine, a health information institution based in the US, stated in January 2023 that the global frequency of migraines ranges between 14% and 15%, accounting for 4.9% of the global disease burden. Consequently, the rising incidence of migraines is propelling the growth of the CGRP inhibitors market.
What Are The Primary Segmentation Parameters In The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
The calcitonin gene-related peptide (cgrp) inhibitors market covered in this report is segmented –
1) By Type Of Inhibitor: Monoclonal Antibodies, Small Molecules, Peptides
2) By Mechanism Of Action: Anti-Calcitonin Gene-Related Peptide (CGRP) Ligand, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
3) By Route of Administration: Oral, Nasal, Intravenous
4) By Treatment: Preventive Migraine Treatment, Acute Migraine Treatment
5) By End User: Hospitals, Specialty Clinics, Mail Order Pharmacies, Retail Pharmacies
Subsegments:
1) By Monoclonal Antibodies: Erenumab (Aimovig), Eptinezumab (Vyepti), Fremanezumab (Ajovy), Galcanezumab (Emgality)
2) By Small Molecules: Ubrogepant, Rimegepant, Atogepant, Zavegepant
3) By Peptides: Calcitonin Gene-Related Peptide (CGRP) Antagonist Peptides, Modified Calcitonin Gene-Related Peptide (CGRP) Analogs, Intranasal Peptide Formulations, Peptide-Based Delivery Systems
Which Emerging Trends Are Reshaping The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Landscape?
Leading organizations in the CGRP inhibitors market are concentrating on creating advanced products to obtain relevant approvals, like CGRP receptor antagonists to increase the effectiveness of migraine treatments, broaden therapeutic applications, and provide more user-friendly methods of administration like oral and intranasal formulations. CGRP receptor antagonists are medications designed to inhibit the CGRP receptor and prevent the signal transmission of migraine-related pain. In April 2023, for instance, AbbVie Inc., a biotech company from the United States, earned approval from the U.S. Food and Drug Administration (FDA) for QULIPTA (atogepant), a treatment for chronic migraines in adults. QULIPTA is an orally administered CGRP receptor antagonist that functions by inhibiting CGRP receptors involved in triggering migraines and thus aids in preventing migraines from occurring.
Who Are The Dominant Players In The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Today?
Major companies operating in the calcitonin gene-related peptide (CGRP) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Kissei Pharmaceutical Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., Shin Nippon Biomedical Laboratories Ltd., Sosei Group Corporation, Nuvie Bio Inc., Vaxxinity Inc., Acherx LLC, AfaSci Inc.
Access The Complete Report Here:
What Are The Emerging Regional Trends Driving The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
North America was the largest region in the calcitonin gene-related peptide (CGRP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin gene-related peptide (CGRP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=24182&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
